Want to see TDOC full AI Analyst Report?
TDOC Stock Chart & Stats
$8.77
$0.03(0.34%)
At close: 4:00 PM EDT
$8.77
$0.03(0.34%)
Day’s Range― - ―
52-Week Range$4.40 - $9.89
Previous CloseN/A
Volume118.45K
Average Volume (3M)4.25M
Market Cap
$1.18B
Enterprise Value$1.80K
Total Cash (Recent Filing)$774.35M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Oct 28, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding181,684,020
10 Day Avg. Volume4,263,428
30 Day Avg. Volume4,248,250
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.89
Price to Sales (P/S)0.49
P/FCF Ratio4.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.71Price Target Upside-12.04% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$2.41B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And LiquidityPositive operating and free cash flow provide internal funding for product investment, reduce reliance on external financing, and improve resilience while profitability remains under development. The substantial cash balance also offers flexibility to manage the business transition.
Integrated Care Scale And Margin ExpansionIntegrated Care combines very broad member reach with improving profitability, suggesting better operating leverage in Teladoc’s core platform. Growth in chronic care, international operations, and hybrid models can support a more durable and diversified revenue base.
Connected-care And AI Product InnovationA unified connected-care model and AI-enabled clinical intelligence can deepen customer integration and improve care coordination across conditions. If adoption develops as planned, these products may strengthen differentiation and expand Teladoc’s strategic relevance.
Bears Say
Persistent Losses And Weak Revenue TrendOngoing operating and net losses limit evidence of a self-sustaining earnings model, while declining revenue makes future operating leverage harder to achieve. Although losses have narrowed, sustained top-line stabilization is still required before profitability can become durable.
BetterHelp Business-model Transition RiskThe shift from cash-pay acquisition toward insurance may improve long-term market access, but it is currently shrinking revenue and leaving the segment near break-even. Execution, reimbursement, and customer-acquisition changes create material uncertainty over recovery timing.
Provider Capacity Constrains Insurance ConversionInsufficient provider capacity can prevent Teladoc from converting insurance demand into completed sessions and revenue, even after credentialing efforts. Scaling the network across markets requires sustained recruitment and activation, creating an operational constraint on the transition.
Teladoc News
TDOC FAQ
What was Teladoc Inc.’s price range in the past 12 months?
Teladoc Inc. lowest stock price was $4.40 and its highest was $9.89 in the past 12 months.
What is Teladoc Inc.’s market cap?
Teladoc Inc.’s market cap is $1.18B.
When is Teladoc Inc.’s upcoming earnings report date?
Teladoc Inc.’s upcoming earnings report date is Oct 28, 2026 which is in 66 days.
How were Teladoc Inc.’s earnings last quarter?
Teladoc Inc. released its earnings results on Jul 29, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.04.
Is Teladoc Inc. overvalued?
According to Wall Street analysts Teladoc Inc.’s price is currently Overvalued.
Does Teladoc Inc. pay dividends?
Teladoc Inc. does not currently pay dividends.
What is Teladoc Inc.’s EPS estimate?
Teladoc Inc.’s EPS estimate is -0.22.
How many shares outstanding does Teladoc Inc. have?
Teladoc Inc. has 181,684,020 shares outstanding.
What happened to Teladoc Inc.’s price movement after its last earnings report?
Teladoc Inc. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -28.322%.
Which hedge fund is a major shareholder of Teladoc Inc.?
Currently, no hedge funds are holding shares in TDOC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teladoc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.71 (-12.04% Downside)
$7.71 (-12.04% Downside)
Blogger Sentiment
Bullish
TDOC Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 336.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.68%
Trailing 12-Months
Company Description
Teladoc Inc.
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
TDOC Company Deck
TDOC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but balanced picture: clear strength and margin expansion in Integrated Care, meaningful product and AI-driven innovation (Teladoc 1 and Pulse), strong liquidity and disciplined cost actions. Offsetting these positives were material near-term challenges in BetterHelp as the business transitions from cash-pay to an insurance/in-network model — accelerated declines in cash-pay users, provider capacity constraints that limited insurance conversion, and a downward revision to consolidated revenue guidance. Management has taken decisive actions (national insurance rollout, provider recruitment/activation initiatives, lower ad spend) to address the issues, but execution risk and timing remain. Overall, the results show operational progress in core businesses and constructive steps to fix the BetterHelp transition, balanced by meaningful short-term revenue pressure and uncertainty in that segment.View all TDOC earnings summariesTDOC Revenue Breakdown
56.44% Teladoc Health Integrated Care
43.56% BetterHelp
TDOC Stock 12 Month Forecast
Average Price Target
$7.71
▼(-12.04% Downside)
Technical Analysis
American Well
―
Doximity
―
VSee Health
―
Hinge Health, Inc. Class A
―
Omada Health, Inc.
―
Ownership Overview
0.65% Insiders
21.44% Mutual Funds
13.62% Other Institutional Investors
41.09% Public Companies and
Individual Investors